|
NCT04723446
|
Efficacy of Mouthwashes in Reducing Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Viral Load in the Saliva |
Completed |
Not Applicable |
May/19/2021 |
Oct/25/2021 |
- Alternative id - TBC
- Interventions - Drug: Corsodyl® Alcohol free -0.2 % Chlorhexidine digluconate|Drug: Colgate Peroxyl® -1.5% Hydrogen peroxide|Other: Oral-B® Gum & Enamel Care -Cetylpyridinium chloride|Other: No rinsing
- Study type - Interventional
- Study results - No Results Available
- Locations - Newham Hospital, London, United Kingdom|Royal London Hospital, London, United Kingdom
- Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Other
- Enrollment - 54
- Age - 18 Years and older (Adult, Older Adult)
- Outcome measures - Viral load changes in the saliva within groups|Difference in the viral load changes in the saliva between groups
|
|
NCT04941131
|
The Role of Chlorhexidine in Minimizing the Viral Load Among COVID-19 Patients |
Not yet recruiting |
Phase 4 |
Jul/01/2021 |
Mar/01/2022 |
- Alternative id - 1485
- Interventions - Drug: Chlorhexidine digluconate, povidone iodine
- Study type - Interventional
- Study results - No Results Available
- Locations - King Abdulaziz University , Faculty of Dentistry, Jeddah, Saudi Arabia
- Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment
- Enrollment - 60
- Age - 21 Years to 80 Years (Adult, Older Adult)
- Outcome measures - quantity of the virus in the saliva measured by Q- PCR
|
|
NCT04719208
|
[COVID-19] Reduction of Sars-CoV-2 Oral Viral Load With Prophylactic Mouth Rinse |
Active, not recruiting |
Not Applicable |
Oct/06/2020 |
Dec/01/2023 |
- Alternative id - [1607808
- Interventions - Other: Water (E) Mouth rinse with the solution provided|Other: Chlorhexidine gluconate (A) Mouth rinse with the solution provided|Other: Hydrogen peroxide (B) Mouth rinse with the solution provided|Other: Betadine (C) Mouth rinse with the solution provided|Other: Alcohol mouthwash (Listerine) (D) Mouth rinse with the solution provided
- Study type - Interventional
- Study results - No Results Available
- Locations - Augusta University, Augusta, Georgia, United States|Augusta University-Dental College of Georgia, Augusta, Georgia, United States
- Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Prevention
- Enrollment - 60
- Age - 18 Years and older (Adult, Older Adult)
- Outcome measures - Change in oral SARS-CoV-2 load in oral cavity of COVID-19 patient using prophylactic mouth rinse
|
|
NCT04603794
|
Efficacy of Mouthwash in Reducing Salivary Carriage of COVID-19 |
Recruiting |
Phase 4 |
Oct/01/2020 |
Nov/01/2020 |
- Alternative id - 2020H0346
- Interventions - Drug: 0.5% Povidone Iodine|Drug: 0.12% Chlorhexidine Gluconate Mouth Rinse|Drug: 1% Hydrogen Peroxide|Drug: 0.9% Normal Saline
- Study type - Interventional
- Study results - No Results Available
- Locations - The Ohio State University Wexner Medical Center, Columbus, Ohio, United States
- Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Prevention
- Enrollment - 60
- Age - 18 Years to 80 Years (Adult, Older Adult)
- Outcome measures - real time reverse transcriptase quantitative PCR|ct values
|
|
NCT04344236
|
Gargling and Nasal Rinses to Reduce Oro- and Nasopharyngeal Viral Load in Patients With COVID-19 |
Withdrawn |
Phase 2 |
Apr/09/2020 |
May/09/2020 |
- Alternative id - s20-00444
- Interventions - Drug: Saline oral/nasal rinse|Drug: 0.5% Povidone/Iodine oral/nasal rinse|Drug: 0.12% Chlorhexidine oral/nasal rinse
- Study type - Interventional
- Study results - No Results Available
- Locations - NYU Langone Health, New York, New York, United States
- Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
- Enrollment - 0
- Age - 18 Years to 79 Years (Adult, Older Adult)
- Outcome measures - Viral load (and/or cycle time to PCR as a proxy for quantitative viral load) in the nasopharynx and oropharynx|Oxygen requirement of the patient|Oxygen saturation of the patient
|
